[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

NO20002129L - Indazol-bioisoster erstatning av catechol i terapeutiske aktive forbindelser - Google Patents

Indazol-bioisoster erstatning av catechol i terapeutiske aktive forbindelser

Info

Publication number
NO20002129L
NO20002129L NO20002129A NO20002129A NO20002129L NO 20002129 L NO20002129 L NO 20002129L NO 20002129 A NO20002129 A NO 20002129A NO 20002129 A NO20002129 A NO 20002129A NO 20002129 L NO20002129 L NO 20002129L
Authority
NO
Norway
Prior art keywords
bioisosterone
indazole
catechol
replacing
active compounds
Prior art date
Application number
NO20002129A
Other languages
English (en)
Other versions
NO20002129D0 (no
Inventor
Anthony Marfat
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20002129D0 publication Critical patent/NO20002129D0/no
Publication of NO20002129L publication Critical patent/NO20002129L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
NO20002129A 1997-11-04 2000-04-26 Indazol-bioisoster erstatning av catechol i terapeutiske aktive forbindelser NO20002129L (no)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US6422997P 1997-11-04 1997-11-04
US6418797P 1997-11-04 1997-11-04
US6402497P 1997-11-04 1997-11-04
US6419897P 1997-11-04 1997-11-04
US6422897P 1997-11-04 1997-11-04
PCT/IB1998/001710 WO1999023077A1 (en) 1997-11-04 1998-10-26 Indazole bioisostere replacement of catechol in therapeutically active compounds

Publications (2)

Publication Number Publication Date
NO20002129D0 NO20002129D0 (no) 2000-04-26
NO20002129L true NO20002129L (no) 2000-07-03

Family

ID=27535645

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20002129A NO20002129L (no) 1997-11-04 2000-04-26 Indazol-bioisoster erstatning av catechol i terapeutiske aktive forbindelser

Country Status (29)

Country Link
US (1) US6391872B1 (no)
EP (1) EP1028946A1 (no)
JP (1) JP2001521926A (no)
CN (1) CN1284948A (no)
AP (1) AP910A (no)
AR (1) AR013746A1 (no)
AU (1) AU754734B2 (no)
BG (1) BG104450A (no)
BR (1) BR9813926A (no)
CA (1) CA2309150A1 (no)
CZ (1) CZ20001621A3 (no)
DZ (1) DZ2640A1 (no)
EA (1) EA200000488A1 (no)
HR (1) HRP20000253A2 (no)
HU (1) HUP0004150A3 (no)
ID (1) ID23921A (no)
IL (1) IL135900A0 (no)
IS (1) IS5465A (no)
MA (1) MA26563A1 (no)
NO (1) NO20002129L (no)
NZ (1) NZ503918A (no)
OA (1) OA11354A (no)
PE (1) PE129199A1 (no)
PL (1) PL340753A1 (no)
SK (1) SK6252000A3 (no)
TN (1) TNSN98200A1 (no)
TR (1) TR200001234T2 (no)
WO (1) WO1999023077A1 (no)
YU (1) YU25000A (no)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0100330A3 (en) * 1997-11-04 2002-03-28 Pfizer Prod Inc Therapeutically active compounds based on indazole bioisostere replacement of catechol in pde4 inhibitors, compositions containing them and their use
UA71971C2 (en) 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
US7141581B2 (en) 1999-07-02 2006-11-28 Agouron Pharmaceuticals, Inc. Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
PE20010306A1 (es) * 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
JP2001031549A (ja) * 1999-07-14 2001-02-06 Pola Chem Ind Inc 真皮コラーゲン線維束再構築剤及びそれを含有する化粧料
MXPA02001448A (es) * 1999-08-12 2002-07-02 American Cyanamid Co Farmacos antiinflamatorios no esteroides e inhibidores de cinasa del receptor del factor de crecimiento epidermico que contiene composicion para el tratamiento o la inhibicion de polipos colonicos y cancer colorrectal.
US6432979B1 (en) 1999-08-12 2002-08-13 American Cyanamid Company Method of treating or inhibiting colonic polyps and colorectal cancer
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
HN2001000008A (es) 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
US7005443B1 (en) * 2000-03-17 2006-02-28 Alcon, Inc. 5-Hydroxy indazole derivatives for treating glaucoma
BR0110302A (pt) 2000-04-18 2003-01-14 Agouron Pharma Compostos de pirazol para inibição de proteìnas cinase, sal e pró-droga farmaceuticamente aceitável, metabólito farmaceuticamente ativo ou sal farmaceuticamente aceitável de metabólito, composição farmacêutica, método de tratamento de condição doentia em mamìferos mediada pela atividade de proteìna cinase, método de modulação ou inibição da atividade de um receptor de proteìna cinase
DE60234510D1 (de) * 2001-04-16 2010-01-07 Eisai R&D Man Co Ltd 1h-indazolverbindungen die jnk hemmen
WO2003024489A2 (en) 2001-09-19 2003-03-27 Altana Pharma Ag Combination of a nsaid and a pde-4 inhibitor
WO2003024456A1 (en) * 2001-09-20 2003-03-27 Eisai Co., Ltd. Methods for treating and preventing migraines
WO2003069740A2 (en) * 2002-02-13 2003-08-21 Koninklijke Philips Electronics N.V. Integrated semiconductor optical device, method and apparatus for manufacturing such a device
US7108868B2 (en) 2002-03-22 2006-09-19 Unigen Pharmaceuticals, Inc. Isolation of a dual cox-2 and 5-lipoxygenase inhibitor from acacia
US7972632B2 (en) 2003-02-28 2011-07-05 Unigen Pharmaceuticals, Inc. Identification of Free-B-Ring flavonoids as potent COX-2 inhibitors
US8034387B2 (en) 2002-04-30 2011-10-11 Unigen, Inc. Formulation of a mixture of free-B-ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments
RU2379031C2 (ru) * 2002-04-30 2010-01-20 Юниджен Фармасьютиклз, Инк. Приготовление смеси флавоноидов со свободным в-кольцом и флаванов как терапевтического агента
EP1569911B1 (en) 2002-12-02 2008-07-02 F. Hoffmann-La Roche Ag Indazole derivatives as crf antagonists
TW200505904A (en) * 2003-02-14 2005-02-16 Wyeth Corp Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
JP4769184B2 (ja) 2003-04-04 2011-09-07 ユニジェン・インコーポレーテッド 哺乳動物の皮膚のケアのためのシクロオキシゲナーゼ（ｃｏｘ）およびリポキシゲナーゼ（ｌｏｘ）の二重の阻害薬の製剤
US6984652B2 (en) * 2003-09-05 2006-01-10 Warner-Lambert Company Llc Gyrase inhibitors
MXPA06009462A (es) 2004-02-27 2007-03-15 Hoffmann La Roche Derivados pirazolo heteroaril fusionados.
US7844309B2 (en) * 2004-02-27 2010-11-30 Nokia Corporation Exchangeable keymat
RU2006134020A (ru) 2004-02-27 2008-04-10 Ф.Хоффманн-Ля Рош Аг (Ch) Конденсированные производные пиразола
CN1922150A (zh) 2004-02-27 2007-02-28 霍夫曼-拉罗奇有限公司 吲唑衍生物以及含有它们的药物组合物
US7601847B2 (en) 2004-10-26 2009-10-13 Wyeth Preparation and purification of 4-(indazol-3-yl)phenols
AP2007004024A0 (en) * 2004-11-29 2007-06-30 Warner Lambert Co Therapeutic pyrazoloÄ3,4-BÜpyridines and indazoles
NZ565872A (en) * 2005-08-15 2011-06-30 Wyeth Corp Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands
BRPI0614341A2 (pt) * 2005-08-15 2011-03-29 Wyeth Corp composto; método para o tratamento de um distúrbio do sistema nervoso central relacionado com o receptor de 5-ht6 ou afetado por ele em um paciente que deste necessite; composição farmacêutica; e processo
EP1919918A2 (en) 2005-08-25 2008-05-14 F.Hoffmann-La Roche Ag P38 map kinase inhibitors and methods for using the same
US7781460B2 (en) 2005-09-05 2010-08-24 Ranbaxy Laboratories Limited Substituted indazoles as inhibitors of phosphodiesterase type-IV
US7915286B2 (en) 2005-09-16 2011-03-29 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
DK1960353T3 (da) * 2005-11-03 2014-05-26 Allergan Inc Prostaglandiner og analoger som midler til sænkning af intraokulært tryk
RU2008127501A (ru) 2006-01-13 2010-02-20 Вайет (Us) Сульфонилзамещенные 1н-индолы в качастве лигандов 5-гидрокситриптаминовых рецепторов
CN101415685B (zh) 2006-01-31 2011-08-24 阿雷生物药品公司 激酶抑制剂及其使用方法
CN101490017B (zh) 2006-02-28 2013-01-23 海利空医疗公司 作为pde4抑制剂的用于治疗的哌嗪类
WO2007120523A2 (en) * 2006-03-31 2007-10-25 Vitae Pharmaceuticals, Inc. 6-(aminoalkyl)indazoles
BRPI0709718A2 (pt) * 2006-04-05 2011-03-29 Wyeth Corp composto; método para tratamento de um transtorno do sistema nervoso central relacionado a ou afetado pelo receptor 5-ht6 em um paciente necessitado; composição farmacêutica; e proceso para a preparação do composto
WO2007120596A1 (en) * 2006-04-12 2007-10-25 Wyeth DIHYDRO[1,4]DIOXINO[2,3-e]INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS
US8012886B2 (en) * 2007-03-07 2011-09-06 Asm Assembly Materials Ltd Leadframe treatment for enhancing adhesion of encapsulant thereto
JP5671236B2 (ja) 2007-03-14 2015-02-18 ランバクシー ラボラトリーズ リミテッド ホスホジエステラーゼ阻害剤としてのピラゾロ（３，４−ｂ）ピリジン誘導体
CN102648284B (zh) * 2009-09-18 2014-09-24 株式会社里维松 多酚衍生物及其制造方法
WO2011143430A1 (en) 2010-05-12 2011-11-17 Abbott Laboratories Indazole inhibitors of kinase
CN103709146B (zh) * 2014-01-15 2015-11-25 中国药科大学 一类含苯并咪唑结构的喹啉-4-胺衍生物、其制法及医药用途
IL304014A (en) 2020-12-30 2023-08-01 Tyra Biosciences Inc Indazole compounds as kinase inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5006520A (en) * 1987-10-13 1991-04-09 Yoshitomi Pharmaceutical Industries, Ltd. Fused pyrazole compounds and pharmaceutical use thereof
EP0338087A4 (en) * 1987-10-13 1991-07-24 Yoshitomi Pharmaceutical Industries, Ltd. Fused pyrazole compounds, process for their preparation, and their medicinal use
US5593997A (en) * 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
AP1147A (en) * 1996-05-03 2003-02-25 Pfizer Substituted indazole derivatives and related compounds.
EP0912558B1 (en) * 1996-06-25 2003-07-09 Pfizer Inc. Substituted indazole derivatives and their use as phosphodiesterase (pde) type iv and tumor necrosis factor (tnf) inhibitors
DE69709493T2 (de) * 1996-06-27 2002-10-31 Pfizer Inc., New York Substituierte Indazolderivate
TR199900481T2 (xx) * 1996-09-04 1999-06-21 Pfizer Inc. �ndazol t�revleri; fosfodiesteraz tip IV inhibit�rleri olarak kullan�mlar�.
HUP0100330A3 (en) * 1997-11-04 2002-03-28 Pfizer Prod Inc Therapeutically active compounds based on indazole bioisostere replacement of catechol in pde4 inhibitors, compositions containing them and their use

Also Published As

Publication number Publication date
EA200000488A1 (ru) 2000-10-30
HUP0004150A2 (hu) 2001-05-28
YU25000A (sh) 2003-12-31
US6391872B1 (en) 2002-05-21
CZ20001621A3 (cs) 2001-08-15
IS5465A (is) 2000-04-19
WO1999023077A1 (en) 1999-05-14
BR9813926A (pt) 2000-09-19
IL135900A0 (en) 2001-05-20
AU754734B2 (en) 2002-11-21
OA11354A (en) 2003-12-23
AU9455298A (en) 1999-05-24
CN1284948A (zh) 2001-02-21
AP9801375A0 (en) 1998-12-31
NZ503918A (en) 2002-03-28
TNSN98200A1 (fr) 2005-03-15
TR200001234T2 (tr) 2000-08-21
JP2001521926A (ja) 2001-11-13
AP910A (en) 2000-12-05
BG104450A (en) 2000-12-29
DZ2640A1 (fr) 2003-03-08
PL340753A1 (en) 2001-02-26
EP1028946A1 (en) 2000-08-23
CA2309150A1 (en) 1999-05-14
SK6252000A3 (en) 2001-11-06
ID23921A (id) 2000-05-25
NO20002129D0 (no) 2000-04-26
MA26563A1 (fr) 2004-12-20
PE129199A1 (es) 1999-12-16
HUP0004150A3 (en) 2001-08-28
AR013746A1 (es) 2001-01-10
HRP20000253A2 (en) 2001-06-30

Similar Documents

Publication Publication Date Title
NO20002129L (no) Indazol-bioisoster erstatning av catechol i terapeutiske aktive forbindelser
ID22878A (id) Komposisi aktif secara terapi
TR199501137A2 (tr) Terapötik olarak aktif bilesenler
NO20003721D0 (no) Farmasøytisk aktivt morfolinol
DE69514087D1 (de) Pharmazeutisch aktive substituierte aromatische verbindungen
IS5425A (is) Læknislyf
EE9800116A (et) Farmatseutiliselt aktiivsed kinasoliini ühendid
IS5452A (is) Meðferðarlega virk efnasambönd byggð á indazól bíóísóstera skiptum á katekóli í PDE4 lötum
NO992806D0 (no) Terapeutiske midler
IS2004B (is) Lyfjasamsetningar sem innihalda vorikónasól
NO980546D0 (no) Farmasöytiske midler
IS4848A (is) Lyfjafræðilega gagnleg efnasambönd
NO995251D0 (no) FremgangsmÕte for administrering av haloterapi
ID26317A (id) Formulasi pelepasan yang diperpanjang
ID21468A (id) Silika endapan yang mengandung suatu bahan aktif
FI974034A0 (fi) Foerfarande foer kapacitetsfoerdelning i ett oeverfoeringssystem foer ett basstationsnaet
DE69800779D1 (de) Photopolymerisierbare Zusammensetzung
NO983090D0 (no) Terapeutiske forbindelser
ID29294A (id) Komposisi farmasi
DE69717068D1 (de) Mehrwalzenbrecher
ID25857A (id) Komposisi farmasi
DE69806425D1 (de) Schlauchanordnungen
ZA9810041B (en) Indazole bioisoster replacement of catechol in therapeutically active compounds.
FI974610A0 (fi) Farmaceutiskt preparat i gelform
ID23531A (id) Komposisi farmasi

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application